
Genor Biopharma Releases Its Annual Results for 2020
Significant progresses in IND, clinical development, NDA/BLA, commercialization, BD and financing NDA/BLA progress – GB226 (Geptanolimab) Priority Review for PTCL, GB242 (infliximab (Remicade) biosimilar) under […]
